Metformin plus radiation and chemo for glioblastoma subtype
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests whether adding metformin to standard radiation and temozolomide (chemo) can improve outcomes for people with newly diagnosed glioblastoma of a specific metabolic subtype. It aims to see if this combination is safer and more effective than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult (18 or older) and recently diagnosed with glioblastoma (grade 4) confirmed by pathology after biopsy/surgery
- Your tumor must be IDH-wildtype and match the study’s specific “OXPHOS+” subtype from central lab testing
- Have had surgery for the brain tumor and start radiation soon (within 7 weeks of diagnosis) with enough recovery and no major ongoing surgical problems
- Be able to take standard chemoradiation (about 60 Gy radiation with temozolomide) and attend all scheduled visits
- Use little or no steroid medicine for brain swelling: either none, or a stable low dose (no more than the limits listed)
- Have enough organ function on blood/urine tests (bone marrow, liver enzymes, and kidney function) and kidney clearance of at least 30 mL/min (with metformin dose capped if clearance is 30–50)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding metformin to the usual treatment for newly diagnosed glioblastoma (GBM) can improve outcomes. It involves taking metformin after surgery along with standard care (the Stupp protocol).
This trial tests giving radiation and chemotherapy before surgery for glioblastoma. It aims to see if this approach is safe and may help improve outcomes for patients whose tumor can be completely removed.
This Phase 2 study tests a combination of chemotherapy and radiation after surgery for certain brain tumors that are “IDH wildtype.” It aims to control the tumor and improve outcomes for people with specific types of glioma or glioblastoma.
This Phase 1/2 study tests a combination of carboplatin chemotherapy with radiation for glioblastoma that has come back. It aims to shrink or control the tumor after standard treatment has already been used.
This study tests a new medicine (MT-125) combined with standard radiation and chemotherapy for people with newly diagnosed glioblastoma that has a specific gene change (MGMT methylated). The goal is to see if it is safe and tolerable, and to look for early signs it might help.
This trial tests combining an immunotherapy drug (adebrelimab) with the standard chemotherapy temozolomide, with or without hyperbaric oxygen treatment, for patients with newly diagnosed glioblastoma who have already completed standard radiation and chemotherapy. The goal is to see if this combination can improve outcomes.
Hear when a new Glioblastoma, IDH-wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.